Best of ASCO - 2014 Annual Meeting

 

Welcome

Tumor-Based Biomarkers

Tumor Biology

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
ERBB2 mutation profiling with next-generation sequencing (NGS) in solid tumors.

Fei Ma

e24264

MET amplification and activating mutation analysis in solid tumors using comprehensive NGS panel.

Xinghao Ai

e24267

PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.

Gennady Bratslavsky

12091

PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study.

Laurie M. Gay

12092

RAS alterations: Next-generation sequencing of 1,526 patients with diverse malignancies reveals prognostic and therapeutic correlates.

Shumei Kato

12096

A gene expression signature of FOXM1-AURKB-CDKN1A to recapitulate molecular characteristics of standardized uptake value of 18F-FDG-PET in breast cancer.

Sung Gwe Ahn

12105

Actionable genomic biomarkers in a low socioeconomic status (SES) population with gastrointestinal (GI) cancers.

Vi Kien Chiu

e24310

Affinity histochemical evaluation of hyaluronan accumulation in solid malignancies of the digestive system.

Darin Taverna

e24270

Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial.

Rosa Isela Gallagher

12103

Association of Caspase 8 polymorphisms with TILs and disease-free survival in primary breast cancer patients.

Pauline Wimberger

e24258

Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.

Fatema A. Legrand

12000

Association of mucosal Fusobacterium with clinical stage and immune gene signatures of rectal adenocarcinoma.

Michael Sangmin Lee

12112

Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors.

Jacob Kaufman

e24274

Associations between mutations of DNA damage response and prognosis in microsatellite instability prevalent tumors.

Zhijie Wang

e24257

Biology and clinical outcomes of estrogen receptor positive (ER+) early primary breast cancer (BC) in older (≥70 years) women—A study based on core needle biopsies (CNB).

Kwok-Leung Cheung

e24253

Biomarker selection for patients participating in phase I clinical trials.

Lauriane Eberst

e24303

BRAF V600 and non-V600 mutations across distinct tumor types.

Qichao Xie

e24297

Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.

Tanya Skamene

TPS12127

Cell-free circulating tumor DNA (cfDNA) to identify germline (GL) and somatic BRCA alterations (alts) in men with advanced prostate cancer (ProsCA).

Victoria M. Raymond

e24287

Characterization of 4q12 amplification in 8819 advanced solid tumor cases.

Jun Wu

e24275

Characterization of genomic alterations, tumor mutational burden and PDL1 expression in 181 Chinese hepatocellular carcinomas.

Qi Ling

e24276

Circadian clock gene PER1 mutations in colorectal cancer (CRC).

Francesca Battaglin

12106

Clinical significance of CD8 and programmed death-ligand 1 (PD-L1) expression in patients with resectable non-small cell lung cancer.

Hye Ree Kim

e24251

Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression.

Sumanta K. Pal

12113

Combination of CT derived radiomic features and lymphovascular invasion status to predict disease recurrence following trimodality therapy in non-small cell lung cancer.

Mohammadhadi Khorrami

e24314

Comparative analysis of target gene exon sequencing by cognitive technology using next generation sequencing platform in Chinese patients with lung cancer.

Xuchao Zhang

e24254

Comparison between Ki-67 biomarker expression in primary breast cancer before and after neoadjuvant therapy.

Jamal Zidan

e24311

Comparison of annotation services for the VA Precision Oncology Program.

Evangelia (Eva) Katsoulakis

12109

Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.

Basak Oyan

e24306

Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation.

Yan Wang

e24281

Comprehensive gene copy number alterations profiling predict efficacy of adjuvant chemotherapy in resected stage II-IIIA lung adenocarcinoma.

Qiaoyun Tan

e24278

Comprehensive genomic analysis of solid tumors by next-generation sequencing.

Waled Bahaj

e24291

Comprehensive tumor genomic testing in the community oncology setting in the United States.

John Marshall

e24304

Computer-extracted features relating to spatial arrangement of tumor infiltrating lymphocytes to predict response to nivolumab in non-small cell lung cancer (NSCLC).

Cristian Barrera

12115

Correlation of tumor mutational burden and predicted functional impact of mutations across cancer types.

Jun Jia

e24296

Detection of germline homologous recombination deficiency (HRD) in patients with metastatic esophagogastric (EG) cancer using clinical next generation sequencing (NGS).

Yelena Yuriy Janjigian

12116

Differential expression of human cyclin G1 (CCNG1) in cancer: A novel biomarker in development for CCNG1 inhibitor therapy.

Joshua Ravicz

e24315

Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).

Matthew Dankner

12093

Effect of the loss of NF1 in breast cancer on pathway activation.

Abde M. Abukhdeir

e24284

Establishment and verification of detecting multiple biomarkers for ovarian cancer by suspensionarray technology and clinical validation for ovarian cancer.

Li Li

e24256

Evaluation of the effect of CXCL13 mRNA expression in early breast cancer outcome: A confirmatory study.

Evangelia Razis

e24286

Exploring the association between somatic molecular features and tumor mutation burden in 513 non–small-cell lung cancer.

Chenchen Zhu

12101

Expression of estrogen receptor variants in ER+ basal-type breast cancers that respond to therapy like ER- breast cancers.

Pat W. Whitworth

e24289

From microarray to RT-qPCR for a multigene panel to predict the risk of breast cancer recurrence.

Skye Hung-Chun Cheng

e24249

Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).

Alberto Puccini

12098

Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.

Madiha Naseem

12107

Genomic characterization of variant histology muscle invasive bladder cancer (MIBC) to predict response to therapy.

Shilpa Gupta

e24290

Genomic landscape of diverse rare tumors: Next-generation sequencing of paired DNA and RNA analysis.

Ryosuke Okamura

12114

Identification of actionable genomic alterations utilizing cfDNA.

Nora Sylvia Sanchez

12110

Identification of URST1 as a prognostic biomarker and therapeutic target for lung cancer.

Atsushi Takano

e24250

Identifying the prognostic significance of genomic alterations in a real-world, EHR-derived clinico-genomic database (CGDB).

Vineeta Agarwala

e24319

Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial.

Cornelia Liedtke

12102

In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict response to HER2-targeted therapy.

Dazhi Liu

e24316

Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer.

Aditya Bardia

12097

Landscape of osimertinib resistant mutations between the two common subtypes of EGFR 19del or L858R in NSCLC.

Yan Zhang

12108

Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN.

Yoshiaki Nakamura

12094

Live tumor cell functional analysis and a xenograft model find co-activated c-Met and ErbB signaling in HER2-negative breast cancer.

Lance G. Laing

e24292

Lung cancer: EGFR-ALK mutation in the high lands.

Leonardo David Villacrés

e24248

Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).

Brian S. Henick

12002

Non-V600 BRAF mutations in advanced malignancies: Prevalence and survival impact.

Ed Kheder

12100

On enabling early detection of cancer via DNA-based signatures in liquid biopsy.

Bahram Ghaffarzadeh Kermani

e24262

Oncogenic mutation within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1.

Jie Gao

e24299

Pan-cancer genomic features of PIK3CA/PTEN and clinical response to everolimus in Chinese population.

Guoling Lin

e24283

Pan-cancer mesenchymal assay to predict response to MEK inhibitors.

Nuala McCabe

12111

PD-L1 expression and TMB status in newly diagnosed metastatic non-small cell lung cancer and their effect on prognosis after EGFR-TKI or platinum-based chemotherapy.

Yanhui Chen

e24294

PD-L1 expression of 742 newly diagnosed advanced respiratory and digestive system tumours in China based on SP142 assay.

Yanhui Chen

e24298

PD-L1 mRNA expression in patients with resectable gastric cancer and adenocarcinoma of the oesophago-gastric junction undergoing perioperative chemotherapy: Results from the FLOT4 phase III trial of the AIO.

Lisa Waberer

e24277

Pharmacological and therapeutic relevance of BRCA1 and BRCA2 variants in solid tumors.

Istvan Petak

e24300

Phosphorylation of AKT kinase substrates to predict response to the AKT inhibitor MK2206 in the I-SPY 2 trial in both HER2- and HER2+ patients.

Julia Dianne Wulfkuhle

12099

Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib.

Terry L. Ng

12095

Prognostic impact of 21-gene recurrence score in patients with node negative breast cancer in China.

Yinduo Zeng

e24255

Prognostic impact of discordance of ER and PR between primary and recurrent breast cancer.

LI Nani

e24295

Prognostic signature of lung adenocarcinoma based on the expression of immune-associated genes.

Xiaoshun Shi

e24260

Quantitative measurement of total erbB2 (H2T), p110 t-erbB2, and erbB2:erbB3 (H23D) heterodimer expression and p110 t-erbB2 in malignant progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).

Yu Zong

12089

Relationship between protein biomarkers of potential chemotherapy response and microsatellite status in 28,101 cancer patients.

Mina Nikanjam

e24259

RNA-Seq data analysis to identify enriched metabolic pathways and a prognostic signature in squamous cell lung cancer.

Jhajaira M Araujo

e24288

Selection of highly stable genes for the transcriptomic evaluation of lung cancer.

I. Tirado-Hurtado

e24318

Serum b-cell maturation antigen levels to predict progression free survival and responses among relapsed or refractory multiple myeloma patients treated on the phase I IRUX trial.

Sean Bujarski

e24313

Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.

Razelle Kurzrock

12118

Single-cell profiling of NSCLC tumor treated with Durvalumab and in combination with Tremelimumab.

Yashaswi Shrestha

12104

SPANOM: A cost-effective method of detecting MSI in ctDNA.

Zhenghang Wang

e24263

The clinical significance of autophagy in patients with non small cell lung cancer.

Nariyasu Nakashima

e24268

Three-fold overestimation of tumor mutation burden using 248 gene panel versus whole exome.

Andrew Nguyen

12117

Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2.

Tobias Kessler

12090

Tumor associated carbohydrate antigens in prostatic adenocarcinoma (PAC): Correlation of sialyl-Tn with malignant phenotype.

Silva Kristo

e24279

Tumor hyaluronan (HA) as a novel biomarker in non-small cell lung cancer (NSCLC).

Jun Gong

e24280

Two years follow-up data of multiple-line treatment in stage IV tumors from a whole exome-guided real-world study of 1,000 Chinese cancer patients.

Qiang Xu

e24282

Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).

Seth Andrew Wander

12016